Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Quick Access Links

Clinical Trials Search Results

Search for

in

Accepting Participants (10)
In Progress (1)

Showing 1-10 of 10

Sorted By:

A-Z
Z-A

Previous Next

(NSABP B-64) EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
participants planning to undergo chemo for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis
A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
A022104: The JANUS Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
A022104: JANUS Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy
A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) [Location: Pierre]
This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment.
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy & Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer & an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
camizestrant vs ET in patients w/ ER+/HER2- early BC w/ risk for disease recurrence who completed treatment & adjuvant ET for 2-5 years. Duration of treatment is 60 months
GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy vs Standard of Care in Pts With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Merck_MK5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Ph 3 Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w/ mCRPC Prev. Treated w/ NHA) & Taxane-based Chemotherapy
Merck_MK5684-004: A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
Ph 3 Study of MK-5684 vs Alt.Abiraterone Acetate or Enzalutamide in Pts w/ mCRPC) that Progressed On /After Prior Treatment With One Next-generation Hormonal Agent (NHA)
NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial (Location: Pierre)
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage).
S1827: MRI BRAIN SURVEILLANCE ALONE VERSUS MRI SURVEILLANCE AND PROPHYLACTIC CRANIAL IRRADIATION (PCI): A RANDOMIZED PHASE III TRIAL IN SMALL-CELL LUNG CANCER (MAVERICK) [Location: Pierre]
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer.

Previous Next